*Corresponding author:P Prakash Babu, Department of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad-500046. Telangana state, India
Received: September 25, 2018; Published: October 04, 2018
To view the Full Article Peer-reviewed Article PDF
Glioblastoma (GBM- GIV astrocytoma) represents the most noted neoplasms of the brain usually reported with dismal prognosis. The term glioblastoma with oligodendroglial component (GBMO) represents the present of oligodendroglial foci in glioblastoma tumors. GBMOs are usually represented with better therapeutic response and concomitant prognostic outcome. We have observed nearly 610 cases of various pathologic grades of astrocytoma from 2009 to 2014 and found the oligodendroglial component among the 40 cases. Nearly in all the cases of GBM and GBMOs received complete resection and was followed by standard therapeutic regime of radiotherapy and chemotherapy with temozolomide. The survival pattern was observed in patients diagnosed with GBM and GBMO. We have looked for the presence of MIB1, p53 and necrosis pattern in selected GBMO sub group. We observe nearly 54% of GBMOs stained positive with p53. Necrosis and MIB1 was observed in most of the GBMO cases. These was statistically significant difference among survival of glioblastoma patients’ and GBMOs. Glioblastoma multiformae patients with oligodendroglial component was observed to have median survival of 16 months while with GBM it was observed to be 12 months. GBMO were found to have significantly longer survival than glioblastoma patients’ and respond well to chemo and radiotherapy.
Keywords: Glioblastoma; GBMO; P53; Mib1; Survival
Abbreviations: GBMO: Glioblastoma with Oligodendroglial Component; WHO: World Health Organization; ICE: Institutional Ethics Committee; KFRC: KIMS Foundation Research Centre